Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese AIDS Vaccine To Be Clinically Tested In U.S. In '10 (Japan)

This article was originally published in PharmAsia News

Executive Summary

A Japanese consortium including the University of Tokyo, Dnavec, and the National Institute of Infectious Diseases plans to begin clinical testing of its AIDS vaccine as early as 2010. The consortium hopes to commercialize the vaccine around 2015. The nasal spray vaccine effort will mark the first such testing of a Japanese-developed AIDS vaccine. Researchers expect the vaccine to increase the number of immune cells available to attack cells infected by HIV. The consortium found that HIV did not propagate among 60% of monkeys given the vaccine prior to being exposed to the virus. The International AIDS Vaccine Initiative will organize clinical tests involving several dozen healthy people. If the vaccine's safety and effectiveness are borne out by those tests, larger scale clinical tests will be carried out. (Click here for more - May Require Paid Subscription

You may also be interested in...

Rejection Rate Soars In Q4 For EU Fast-Track Requests

October and November 2020 were bad months for companies seeking to have their planned EU filings fast-tracked through the centralized drug review system at the European Medicines Agency.

Biden Regulatory Freeze May Pause SUNSET Rule

Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.

Canada Boosts Postmarket Device Safety With New Reporting Rules

Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts